Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations
The negotiation program was created as part of the 2022 Inflation Reduction Act, which capped years of debate over whether the federal government should be allowed to haggle directly with pharmaceutical companies over the prices of drugs in Medicare.